AbCellera Biologics Inc. (ABCL)
2.52
-0.07 (-2.70%)
At close: Mar 25, 2025, 3:59 PM
2.50
-0.47%
Pre-market: Mar 26, 2025, 07:24 AM EDT
-2.70% (1D)
| Bid | 2.45 |
| Market Cap | 749.44M |
| Revenue (ttm) | 29.19M |
| Net Income (ttm) | -164.88M |
| EPS (ttm) | -0.55 |
| PE Ratio (ttm) | -4.57 |
| Forward PE | -4.89 |
| Analyst | Buy |
| Ask | 2.59 |
| Volume | 3,994,082 |
| Avg. Volume (20D) | 4,098,576 |
| Open | 2.60 |
| Previous Close | 2.59 |
| Day's Range | 2.45 - 2.60 |
| 52-Week Range | 2.11 - 4.75 |
| Beta | 0.45 |
About ABCL
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 11, 2020
Employees 596
Stock Exchange NASDAQ
Ticker Symbol ABCL
Website https://www.abcellera.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 178.33% from the latest price.
Stock ForecastsNext Earnings Release
AbCellera Biologics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-11.3%
AbCellera Biologics shares are trading lower after...
Unlock content with
Pro Subscription
2 months ago
+6.86%
AbCellera Biologics shares are trading higher after the company announced the expansion of its collaboration with AbbVie to include the discovery of t-cell engages in oncology.
